Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Hepatology. 2014 Nov 25;61(1):200–213. doi: 10.1002/hep.27396

Fig. 1.

Fig. 1

Rapamycin treatment effectively inhibits AKT/Ras induced hepatocarcinogenesis. (A) Gross images of livers, (B) liver weight and liver to body weight ratio of AKT/Ras mice treated with vehicle (Veh) or Rapamycin (Rapa) for 7 weeks. Data are presented as mean ± SEM. ****P<0.0001. (C) Hematoxylin & eosin (HE) and Ki67, (D) HA-tag, (E) p-AKT, p-ERK and p-mTOR staining in Rapamycin treated ATK/Ras mouse liver tissues. Magnifications: 100× (C&D); 400× (E and insets). 148×190mm (300 × 300 DPI)